Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Sleep Apnea01:21

Sleep Apnea

449
Sleep apnea is a condition where breathing stops intermittently during sleep, often leading to significant health issues. Each episode can last from 10 to 20 seconds or more and is frequently accompanied by a brief arousal from sleep. This disturbance, largely unnoticed by the individual, can lead to severe daytime fatigue. Commonly, individuals seek help after being informed by their partners about loud snoring and noticeable breathing pauses during sleep.
The condition is more prevalent among...
449
Management of Insomnia01:19

Management of Insomnia

499
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
499
Sedatives and Hypnotics Drugs: Miscellaneous Agents01:17

Sedatives and Hypnotics Drugs: Miscellaneous Agents

477
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
477
Sedatives and Hypnotics: Overview01:23

Sedatives and Hypnotics: Overview

1.3K
Sedatives are drugs that alleviate anxiety, while hypnotics induce sleep. Both classes of medication suppress neuronal activity, leading to a calming effect for sedatives and facilitating sleep for hypnotics.
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...
1.3K
Inhaled Medications01:23

Inhaled Medications

687
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
687
CNS Depressants: Barbiturates and Benzodiazepines01:14

CNS Depressants: Barbiturates and Benzodiazepines

1.1K
CNS depressants include drugs from the category of barbiturates and benzodiazepines. They are valuable medications for managing anxiety disorders and insomnia. Barbiturates, once used to induce and maintain sleep, have been replaced mainly by benzodiazepines due to barbiturate's toxicity, tolerance, and overdose risks. They interact with GABAA receptors, leading to sedation at low doses and potentially coma and death at higher doses. Phenobarbital, a long-acting barbiturate, possesses...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prediction of 90-day mortality after acute ischemic stroke using the National Institutes of Health Stroke Scale alone.

Clinical neurology and neurosurgery·2026
Same author

GLP-1 RAs in Substance Use Disorders: Emerging Evidence and Future Directions.

Cardiology in review·2026
Same author

Congenital Atrioventricular Block: Comprehensive Review of Pathophysiology, Management, and Future Therapeutic Directions.

Cardiology in review·2025
Same author

Flavoprotein fluorescence elevation is a marker of mitochondrial oxidative stress in patients with retinal disease.

Frontiers in ophthalmology·2024
Same author

Lipoprotein(a): A Review of Risk Factors, Measurements, and Novel Treatment Modalities.

Cardiology in review·2024
Same author

A New Era in Stroke Care.

Cardiology in review·2024

Related Experiment Video

Updated: Jan 8, 2026

Drug-Induced Sleep Endoscopy DISE with Target Controlled Infusion TCI and Bispectral Analysis in Obstructive Sleep Apnea
07:54

Drug-Induced Sleep Endoscopy DISE with Target Controlled Infusion TCI and Bispectral Analysis in Obstructive Sleep Apnea

Published on: December 6, 2016

20.4K

Medications for Obstructive Sleep Apnea.

Jason Macanian1, Noah Schechter1, William H Frishman1,2

  • 1From the Department of Medicine, Westchester Medical Center, New York Medical College, Valhalla, NY.

Cardiology in Review
|December 17, 2025
PubMed
Summary

New oral medications, including GLP-1 receptor agonists, offer effective treatments for obstructive sleep apnea (OSA) by promoting weight loss. Other novel drugs may provide rapid relief independent of weight, improving patient adherence and outcomes.

Keywords:
AD109GLP-1 receptor agonistsobstructive sleep apneatirzepatideweight loss

More Related Videos

Author Spotlight: Traditional Chinese Medicine for Sleep Disorders in Acute COPD — A Safe, Cost-Effective Approach
04:53

Author Spotlight: Traditional Chinese Medicine for Sleep Disorders in Acute COPD — A Safe, Cost-Effective Approach

Published on: October 18, 2024

1.3K
Author Spotlight: Utilizing Traditional Chinese Acupuncture of the Ear to Improve Sleep Disorders
05:34

Author Spotlight: Utilizing Traditional Chinese Acupuncture of the Ear to Improve Sleep Disorders

Published on: August 18, 2023

3.3K

Related Experiment Videos

Last Updated: Jan 8, 2026

Drug-Induced Sleep Endoscopy DISE with Target Controlled Infusion TCI and Bispectral Analysis in Obstructive Sleep Apnea
07:54

Drug-Induced Sleep Endoscopy DISE with Target Controlled Infusion TCI and Bispectral Analysis in Obstructive Sleep Apnea

Published on: December 6, 2016

20.4K
Author Spotlight: Traditional Chinese Medicine for Sleep Disorders in Acute COPD — A Safe, Cost-Effective Approach
04:53

Author Spotlight: Traditional Chinese Medicine for Sleep Disorders in Acute COPD — A Safe, Cost-Effective Approach

Published on: October 18, 2024

1.3K
Author Spotlight: Utilizing Traditional Chinese Acupuncture of the Ear to Improve Sleep Disorders
05:34

Author Spotlight: Utilizing Traditional Chinese Acupuncture of the Ear to Improve Sleep Disorders

Published on: August 18, 2023

3.3K

Area of Science:

  • Sleep Medicine
  • Pharmacology
  • Obesity Medicine

Background:

  • Obstructive sleep apnea (OSA) is a prevalent disorder characterized by airway collapse and sleep disruption.
  • Continuous positive airway pressure (CPAP) is the standard treatment but faces adherence challenges.
  • Weight loss is a key intervention for obese patients with OSA, reducing airway adiposity and apnea severity.

Purpose of the Study:

  • To review emerging oral pharmacotherapies for OSA.
  • To evaluate the efficacy of GLP-1 receptor agonists and other novel agents.
  • To discuss potential improvements in OSA management and patient outcomes.

Main Methods:

  • Review of clinical trials (e.g., SURMOUNT-OSA, SCALE Sleep Apnea) for GLP-1 receptor agonists.
  • Analysis of studies on other oral treatments like atomoxetine and aroxibutyin (AD109).
  • Evaluation of mechanisms of action, including weight loss and anti-inflammatory effects.

Main Results:

  • GLP-1 receptor agonists significantly reduce the apnea-hypopnea index in obese patients with OSA, primarily through weight loss.
  • Emerging oral agents like atomoxetine and aroxibutyin show promise for rapid symptom relief, independent of weight.
  • These new treatments may improve adherence and reduce cardiometabolic complications compared to CPAP.

Conclusions:

  • Novel oral medications represent a significant advancement in OSA treatment.
  • Weight loss induced by GLP-1 receptor agonists is a primary driver of efficacy.
  • Future research should focus on long-term outcomes, patient selection, and combination therapies.